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Hetlioz® (tasimelteon) is the ﬁrst approved treatment in the United States for Non-24-Hour Sleep-Wake
Disorder (Non-24). We present here data on the in vitro binding afﬁnity of tasimelteon for both human
melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes.
Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1e4.4 times
greater afﬁnity for the MT2 receptor believed to mediate circadian rhythm phase-shifting
(Ki ¼ 0.0692 nM and Ki ¼ 0.17 nM in NIH-3T3 and CHOeK1 cells, respectively), than for the MT1 re-
ceptor (Ki ¼ 0.304 nM and Ki ¼ 0.35 nM, respectively). Tasimelteon was also shown to have no appre-
ciable afﬁnity for more than 160 other pharmacologically relevant receptors and several enzymes.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Circadian rhythms are regulated by an endogenous circadian
pacemaker that resides in the suprachiasmatic nuclei (SCN) in
mammals. This pacemaker is the Master Body Clock that regulates
the circadian rhythms of biological processes including the secre-
tion of hormones such asmelatonin and cortisol, sleep-wake cycles,
alertness and performance patterns, metabolism and cardiovascu-
lar processes (Lockley et al., 2007, 2008). In human, the endogenous
rhythm of the SCN is typically slightly longer than 24 h and
therefore must be entrained (synchronized) to the 24-h day. The
strongest zeitgeber responsible for entrainment is the dailyBSA, Bovine serum albumin;
r Agonist; EC50, 50% of the
acid; Emax, Maximal effect;
S, 4-(2-hydroxyethyl)-1-
ethylxanthine; IC50, Concen-
ociation constant for the in-
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r Ltd. This is an open access articllightedark cycle, detected primarily by the intrinsically photosen-
sitive ganglion cells of the retina (Czeisler and Gooley, 2007;
Ramsey et al., 2013).
Disruptions in a person's circadian rhythms have been recog-
nized to play a signiﬁcant role in the etiology of a number of serious
and chronic disorders, including obesity (Karlsson et al., 2001),
diabetes (Morikawa et al, 2005), breast cancer (Davis et al., 2001;
Schernhammer et al, 2001), colorectal cancer (Schernhammer
et al, 2003), cardiovascular diseases (Vyas et al, 2012; Ruger and
Scheer, 2009; Knutsson, 2003), depression (Boyce and Barriball,
2010; Monteleone and Maj, 2008; Turek, 2007), and circadian-
rhythm sleep-wake disorders (Sack et al, 2007) like Non-24-Hour
Sleep-Wake Disorder (Non-24) (Lockley et al., 2007; Skene et al.,
1999). Non-24 is a serious, debilitating, chronic disorder that oc-
curs when individuals are unable to synchronize their endogenous
circadian clock to the 24-h light-dark cycle (American Psychiatric
Association, 2013; American Academy of Sleep Medicine, 2005).
The majority of reported cases of Non-24 occur in blind patients
with no conscious perception of light (Lockley et al., 2007;
Uchiyama and Lockley, 2009). The growing understanding of the
importance of circadian regulation in these complex disorders is
expected to spawn the development of speciﬁcally designed
circadian regulators that can address the underlying circadian
component of these conditions.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Chemical structure of tasimelteon.
Table 1
Binding afﬁnity of tasimelteon at the human melatonin receptors.
Cell system Ki (nM) Ki ratio
MT1 MT2 MT1/MT2
NIH-3T3 0.35 0.17 2.1
CHOeK1 0.304 0.0692 4.4
C. Lavedan et al. / Neuropharmacology 91 (2015) 142e147 143Tasimelteon is a novel structurally unique molecular entity,
chemically designated as (1R, 2R)-N-[2- (2,3-dihydrobenzofuran-4-
yl)cyclopropylmethyl]propanamide, containing two chiral centers
that was developed for the treatment of Non-24. Its molecular
formula is C15H19NO2, and the molecular weight is 245.32. Tasi-
melteon differs structurally from melatonin and drugs with known
melatonin agonist activity, in particular by its distinct aromatic
group and linker (Fig. 1). Tasimelteon bears also no structural
relationship to any other approved active substance.
Tasimelteon was speciﬁcally developed to treat the underlying
circadian basis of Non-24, and has undergone rigorous safety
evaluation (Swick et al., 2014; Sliman et al., 2014; Quera-Salva et al.,
2014; Lockley et al., unpublished results). Non-24 is a circadian
rhythm disorder, which primarily affects totally blind individuals,
characterized by the inability to entrain the master body clock to
the 24-h lightedark cycle (American Psychiatric Association, 2013;
American Academy of Sleep Medicine, 2005). It is estimated that
seventy percent of blind individuals with no light perception have
Non-24 (Sack and Lewy, 2001). Patients with Non-24 have pro-
longed periods of misalignment of circadian rhythms, including the
timing of melatonin and cortisol secretion and the sleep-wake cy-
cle, which are associated with signiﬁcant impairments in social and
occupational functioning, and marked subjective distress
(American Psychiatric Association, 2013).
Studies reported here investigated the binding characteristics of
tasimelteon for a wide range of receptors and other pharmaco-
logical targets, in particular the G protein-coupled melatonin MT1
and MT2 receptors, which are expressed in the central nervous
system and in peripheral tissues (Dubocovich and Markowska,
2005). Results point to the unique receptor binding proﬁle of
tasimelteon, which acts as a selective and potent DMRA with
greater afﬁnity for the MT2 receptor than for the MT1 receptor, andFig. 2. Afﬁnity of tasimelteon at the human melatonin receptors MT1 and MT2 in NIH-3T3 ce
error of the mean for the MT1 receptor (left graph) and for the MT2 receptor (right graph)no appreciable afﬁnity for more than 160 other pharmacologically
relevant receptors and enzymes, including the gamma-
aminobutyric acid (GABA) receptor complex and receptors that
bind neuropeptides, cytokines, serotonin, noradrenaline, acetyl-
choline, and opiates.
2. Materials and methods
The speciﬁc afﬁnity of tasimelteon for the MT1 and MT2 receptors was evaluated
in two independent experiments using human recombinant receptors and radio-
ligand binding assays. The selectivity of the receptor binding was further evaluated
by determining the afﬁnity for more than 160 other receptors and several enzymes.
Furthermore, inhibition of forskolin-stimulated cyclic adenosine monophosphate
(cyclic AMP or cAMP) accumulation was conducted in NIH-3T3 cells stably
expressing the human MT1 and MT2 receptors.
2.1. Binding assays at the MT1 and MT2 receptors
In a ﬁrst experiment, two lines of NIH-3T3 cells were used; one cell line stably
expressed the human MT1 receptor while the second cell line stably expressed the
human MT2 receptor. Cells were maintained and passaged as attached monolayers
in Dulbecco's Modiﬁed Eagle Medium containing D-glucose, 10 mM HEPES, 10% heat
inactivated calf serum and 500 mg/mL geneticin. Cultures were incubated in vented
tissue culture ﬂasks at 37 C in a humidiﬁed atmosphere containing 5% CO2. Cells
were harvested and frozen as pellets at 80 C. Membrane homogenates were
prepared in assay buffer (50 mM TRIS containing 12.5 mM MgCl2 and 2 mM EDTA,
pH 7.4 at 37 Cwith HCl) fortiﬁedwith 10 mg/mL aprotinin and leupeptin and 100 mM
PMSF, using a Dounce homogenizer. The resulting homogenate was centrifuged
(45,000  g, 10 min, 4 C) and the pellet was resuspended in fortiﬁed assay buffer at
a ratio of 0.25 mL per original ﬂask of cells and frozen in aliquots at80 C until use.
Binding assays were performed in duplicate in a total volume of 0.2 mL containing
0.16 mL membrane homogenate diluted appropriately, 0.02 mL 2-[125I]iodomela-
tonin (0.1 or 0.2 nM ﬁnal concentration for MT1 or MT2, respectively) and 0.02 mL
assay buffer, melatonin or tasimelteon. Nine concentrations of tasimelteon
(0.001 nM, 0.01 nM, 0.03 nM, 0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, and 100 nM) and 5
concentrations of melatonin (0.01 nM, 0.1 nM, 1 nM, 10 nM, and 100 nM) were used
for each MT1 or MT2 binding assay. Non-speciﬁc binding was determined in the
presence of 10 mM melatonin. Assays were initiated by the addition of membranells. Data used for the non-linear regression analysis are shown as the mean ± standard
stably expressed in NIH-3T3 cells.
Fig. 3. Afﬁnity of tasimelteon at the human melatonin receptors MT1 and MT2 in CHOeK1 cells. Data used for the non-linear regression analysis are shown as the mean ± standard
error of the mean for the MT1 receptor (left graph) and for the MT2 receptor (right graph) expressed in CHOeK1 cells.
C. Lavedan et al. / Neuropharmacology 91 (2015) 142e147144homogenates and incubated for 60 min at 37 C. Assays were terminated by rapid
ﬁltration onto Whatman GF/B ﬁlters with a Brandel cell harvester. Filters were
washed 3 times with 4 mL ice-cold 20 mM TRIS containing 2 mM MgCl2, pH 7.4 at
25 C. Bound radioactivity was quantitated by gamma emission spectrometry. Data
were analyzed by a 4-parameter logistic, non-linear least squares regression
(DeLean et al., 1978) to yield IC50 values (concentration producing 50% of the
maximal effect), which were converted to dissociation constant for the inhibitor (Ki)
values (Cheng and Prusoff, 1973).
In a second experiment, two lines of CHOeK1 cells were used; one cell line
expressed the human MT1 receptor while the other expressed the human MT2 re-
ceptor. Radioligand binding assays were performed with 0.05 nM 2-[125I]iodome-
latonin used as the ligand, with a 4 h incubation at 25 C in 25 mM HEPES, pH 7.4,
5 mM MgCl, 1 mM CaCl, 0.1% BSA. 6-Chloromelatonin (1 mM) was used as non-
speciﬁc ligand. The reference compounds used for the MT1 or MT2 binding assays
were melatonin and 4-P-PDOT, respectively; 4-P-PDOT was used in this second
experiment because it was shown to have substantially higher afﬁnity for the MT2
receptor than for the MT1 receptor (Browning et al., 2000). Six concentrations ofFig. 4. Inhibition by tasimelteon of forskolin-stimulated cAMP accumulation in NIH-3T3 ce
linear regression analysis are shown as the mean ± standard error of the mean for the MTtasimelteon (0.1 nM, 0.3 nM, 1 nM, and 3 nM, 10 nM and 30 nM for MT1; 0.01 nM,
0.03 nM, 0.1 nM, 0.3 nM, 1 nM, and 3 nM for MT2) were used in triplicate batches,
with duplicate assays for each batch. IC50 values were determined by a non-linear,
least squares regression analysis using MathIQ™ (ID Business Solutions Ltd., UK).
Ki values were calculated according to the equation of Cheng and Prusoff (Cheng and
Prusoff, 1973) using the observed IC50 of the tested compound, the concentration of
radioligand employed in the assay, and the historical values for the dissociation
constant of the ligand (obtained experimentally at MDS Pharma Services).
2.2. Cyclic adenosine monophosphate assays
Cyclic AMP assays were performed using NIH-3T3 cells stably expressing human
MT1 or MT2 receptors. Cells were incubated in culture media containing 1 mM IBMX
and 10 mM forskolin for 10 min at 37 C in the presence of increasing concentrations
(1 pMe10 mM) of melatonin or tasimelteon. Assays were terminated by the addition
of 0.1 N HCl. Following centrifugation, supernatants were collected and stored
at 20 C until assayed. Cyclic AMP levels were measured by radioimmunoassaylls stably expressing human melatonin receptors MT1 and MT2. Data used for the non-
1 receptor (left graph) and for the MT2 receptor (right graph).
Table 2
List of receptors for which tasimelteon (10 mM) did not inhibit or stimulate binding by more than 50%.
Receptor Receptor Receptor
Adenosine A1 GABAB1A Potassium channel [SKCA]
Adenosine A2A GABAB1B Potassium channel HERG
Adenosine A3 Gabapentin Progesterone
Adrenergic a1A Galanin GAL1 Progesterone PR-B
Adrenergic a1B Galanin GAL2 Prostanoid CRTH2
Adrenergic a1D Glucocorticoid Prostanoid DP
Adrenergic a2 Glutamate, AMPA Prostanoid EP2
Adrenergic a2A Glutamate, Kainate Prostanoid EP4
Adrenergic a2C Glutamate, NMDA Prostanoid, thromboxane A2
Adrenergic b1 Glycine, strychnine-sensitive Purinergic P2X
Adrenergic b2 Growth hormone secretagogue Purinergic P2Y
Adrenergic b3 Histamine H1, central Retinoid X Receptor RXRa
Adrenomedullin AM1 Histamine H2 Rolipram
Adrenomedullin AM2 Histamine H3 Ryanodine RyR3
Aldosterone Histamine H4 Serotonin 5-HT1
Anaphylatoxin C5a Hypocretin (orexin) receptor 1 Serotonin 5-HT1A
Androgen Hypocretin (orexin) receptor 2 Serotonin 5-HT1B
Angiotensin AT1 Imidazoline I2, central Serotonin 5-HT2
Angiotensin AT2 Inositol trisphosphate IP3 Serotonin 5-HT2A
Apelin (APJ) Insulin Serotonin 5-HT2B
Atrial natriuretic factor Interleukin IL-1 Serotonin 5-HT2C
Bombesin BB1 Interleukin IL-2 Serotonin 5-HT3
Bombesin BB2 Interleukin IL-6 Serotonin 5-HT4
Bombesin BB3 Leptin Serotonin 5-HT5A
Bradykinin B1 Leukotriene (LTB4) Serotonin 5-HT6
Bradykinin B2 Leukotriene, Cysteinyl CysLT1 Sigma s1
Calcitonin Leukotriene, Cysteinyl CysLT2 Sigma s2
Calcitonin gene-related peptide CGRP1 Melanocortin MC1 Sodium channel, Site 2
Calcium channel L-type Melanocortin MC3 Somatostatin sst1
Calcium channel N-type Melanocortin MC4 Somatostatin sst2
Cannabinoid CB1 Melanocortin MC5 Somatostatin sst3
Cannabinoid CB2 Motilin Somatostatin sst4
Chemokine CCR1 Muscarinic M1 Somatostatin sst5
Chemokine CCR2B Muscarinic M2 Tachykinin NK1
Chemokine CCR4 Muscarinic M3 Tachykinin NK2
Chemokine CCR5 Muscarinic M4 Tachykinin NK3
Chemokine CX3CR1 Muscarinic M5 Thromboxane A2
Chemokine CXCR2 (IL-8RB) N-formyl peptide receptor FPR1 Thyroid hormone
Cholecystokinin CCK1 (CCKA) N-formyl peptide receptor- Like FPRL1 Thyrotropin releasing hormone
Cholecystokinin CCK2 (CCKB) Neurokinin NK1 Transforming growth factor-b
Colchicine Neuromedin U NMU1 Transporter, adenosine
Corticotropin releasing factor CRF1 Neuromedin U NMU2 Transporter, choline
Dopamine D1 Neuropeptide Y, Y1 Transporter, dopamine
Dopamine D2L Neuropeptide Y, Y2 Transporter, GABA
Dopamine D2S Neurotensin NT1 Transporter, monoamine
Dopamine D3 Nicotinic acetylcholine Transporter, norepinephrine
Dopamine D4.2 Nicotinic acetylcholine a1, Transporter, serotonin
Dopamine D5 Nicotinic acetylcholine a7, Tumor necrosis factor
Endothelin ETA Opiate d (OP1, DOP) Urotensin II
Endothelin ETB Opiate k (OP2, KOP) Vanilloid
Epidermal growth factor Opiate m (OP3, MOP) Vascular endothelial growth factor
Erythropoietin EPOR Orphanin ORL1 Vasoactive intestinal peptide
Estrogen ERa Phorbol ester Vasoactive intestinal peptide 1
Estrogen ERb Platelet activating factor Vasopressin V1A
G Protein-coupled receptor GPR103 Platelet-derived growth factor Vasopressin V1B
G Protein-coupled receptor GPR8 Potassium channel [KA] Vasopressin V2
GABAB Potassium channel [KATP] Vitamin D3
C. Lavedan et al. / Neuropharmacology 91 (2015) 142e147 145(Amersham). Radioactivity was quantitated by gamma emission spectrometry.
Three separate experiments were performed in duplicate. Data were analyzed by a
4-parameter logistic, non-linear least squares regression (DeLean et al., 1978) to
yield concentration producing 50% of the maximal effect (EC50) and maximal effect
(Emax) values.
2.3. Extended binding proﬁle
Standard radioligand binding and enzyme inhibition assays were performed on
receptors, binding sites or enzyme systems obtained from various sources, including
human, rat, mouse, guinea pig, rabbit, hamster, and bovine tissues (see
Supplemental Information), using the ProﬁlingScreen and DiscoveryScreen panels
(Panlabs) which consisted of 56 radioligand binding assays and 7 enzyme assays,
respectively, and the SpectrumScreen panel (MDS Pharma Services) that included
170 pharmacological relevant targets (see Supplemental Information). In addition,
the GABAA benzodiazepine and GABAB binding sites were also tested independently(Panlabs biochemical pharmacology assays). Tasimelteon was used at a concentra-
tion of 10 mM except for 2 enzyme assays (Protein kinases C: PKCa and PKCb) where
it was used at 100 mM, and for the melatonin receptors in the SpectrumScreen panel
where 4 concentrations (10 nM, 0.1 mM, 1 mM and 10 mM) were tested. A response
was considered signiﬁcant if therewas50% inhibition or stimulation for the assays.
The afﬁnity of tasimelteon (10 mM) for the human hypocretin (orexin) receptor 1
expressed in transfected CHO cells, and for the human hypocretin (orexin) receptor 2
expressed in transfected HEK-293 cells, was determined in radioligand binding as-
says (Euroﬁns Cerep SA, Celle l'Evescault, France).
3. Results
Tasimelteon potently inhibits 2-[125I]iodomelatonin (0.1 or
0.2 nM) binding at the human MT1 and MT2 receptors stably
C. Lavedan et al. / Neuropharmacology 91 (2015) 142e147146expressed in NIH-3T3 cells. In this experiment, tasimelteon dis-
played comparable potency to melatonin at the MT1 receptor and
stronger potency than melatonin (P < 0.05) at the MT2 receptor
(Fig. 2). Non-linear regression analysis of the data for the MT1 re-
ceptor yielded pKi values (±standard error of the mean) of
9.39 ± 0.02 (Ki ¼ 0.41 nM) for melatonin and pKi ¼ 9.45 ± 0.04
(Ki¼ 0.35 nM) for tasimelteon (Table 1); for theMT2 receptor values
were pKi ¼ 9.57 ± 0.03 (Ki ¼ 0.27 nM) for melatonin and
pKi ¼ 9.77 ± 0.07 (Ki ¼ 0.17 nM) for tasimelteon (Table 1). Analysis
of similar binding assays performed with CHOeK1 cells conﬁrmed
a higher afﬁnity of tasimelteon for the MT2 receptor, with
Ki ¼ 0.304 nM and Ki ¼ 0.0692 ± 0.007 nM for MT1 and MT2
respectively (Fig. 3, Table 1). In CHOeK1 cells, positive controls
melatonin and 4-P-PDOT had Ki values of 0.246 ± 0.039 nM and
0.273 ± 0.023 nM for MT1 and MT2, respectively. Binding kinetics
were best ﬁt to a one-site binding model, suggesting a single re-
ceptor interaction. Taken together, results indicate that tasimelteon
is a DMRA with 2.1e4.4 times greater afﬁnity for the MT2 receptor
than for the MT1 receptor (Table 1). For melatonin, afﬁnity for the
MT2 receptor was 1.5 fold higher than for the MT1 receptor in NIH-
3T3 cells.
Tasimelteon was shown to induce a potent, concentration-
dependent inhibition of forskolin-stimulated cAMP accumulation
in NIH-3T3 cells stably expressing human MT1 (pEC50 ¼ 9.1 ± 0.1,
EC50 ¼ 0.74 nM, and Emax ¼ 59 ± 1%) or expressing human MT2
(pEC50 ¼ 9.0 ± 0.1, EC50 ¼ 0.1 nM, and Emax ¼ 60 ± 3%) receptors
(Fig. 4).
No signiﬁcant responses (50% inhibition or stimulation) were
observed in any radioligand receptor binding assay (Table 2) and
enzyme assays (Table 3), except for both melatonin receptors MT1
and MT2 assays for which approximately 100% inhibition was
achieved at 10 nM. Because of overlaps between the ProﬁlingScreen
and DiscoveryScreen panels (Panlabs) and the SpectrumScreen
panel (MDS Pharma Services) forty two receptors were tested
twice, in some cases with a different assay (i.e. different ligand or
different source of receptor); results were consistent in all cases,
showing no signiﬁcant binding afﬁnity for these receptors.4. Discussion and conclusions
Tasimelteon was shown to have full agonist activity at both
melatonin receptors, with greater afﬁnity for the MT2 receptor as
compared to the MT1 receptor in 2 independent experiments
where the human melatonin receptors were expressed in different
cell lines. The Ki values of tasimelteon showed numerical differ-
ences between cell lines for each melatonin receptor, and between
melatonin receptors for each cell line, but remained within the
same order of magnitude (Table 1). Such differences are not un-
expected for studies with different experimental conditions and
may be due to variations in cellular environment (Nelson and
Challiss, 2007), receptor reserve (Zhu, 1993) or receptor expres-
sion and coupling (Luttrell, 2006), which can affect the Ki estima-
tion (Van et al., 1997). Results were consistent across experimentsTable 3
List of enzymes not inhibited by tasimelteon
Enzyme Tasimelteon (mM)
Calpain 10
Nitric oxide synthase, constitutive 10
Nitric oxide synthase, inducible 10
Protein kinase, EGF receptor kinase 10
Protein kinase, PKCa 100
Protein kinase, PKCb 100
Protein phosphatase, calcineurin 10in demonstrating the binding afﬁnity of tasimelteon for both
melatonin receptors, and in indicating a higher MT1/MT2 Ki ratio.
MT1 andMT2 melatonin receptors are present in several areas of
the central nervous system, including the SCN, the pars tuberalis,
and the retina, as well as in peripheral tissues such as kidney,
pancreas, testes, adrenal cortex, and the immune and cardiovas-
cular systems (Dubocovich and Markowska, 2005). The MT1 re-
ceptor has been implicated in the modulation of neuronal ﬁring
(Liu et al, 1997; Jin et al, 2003), cardiac vessel constriction (Krause
et al., 1995), reproductive functions (Johnston et al., 2003a;
Johnston et al, 2003b), and metabolic functions (Peschke, 2008;
Kemp et al., 2002). The MT2 receptor is believed to mediate circa-
dian rhythm phase-shifting (Liu et al, 1997; Dubocovich et al., 1998,
2005; Hunt et al., 2001), and was recently implicated in the regu-
lation of sleep (Ochoa-Sanchez et al, 2011).
While the binding afﬁnity of tasimelteon for the melatonin re-
ceptors has not been determined in vivo, the clinical effects of
tasimelteon are consistent with the results of the in vitro experi-
ments. Tasimelteon has demonstrated the ability to phase-advance
the sleep-wake cycle and improve nighttime sleep and daytime
sleep (Lockley et al., 2013a, 2013b; Rajaratnam et al, 2009; Torres
et al., 2014). Tasimelteon has also demonstrated its ability to
phase-advance and entrain the SCN as measured by the circadian
rhythm proﬁle of the hormones melatonin and cortisol (Lockley
et al, 2013a, 2013b; Rajaratnam et al, 2009).
Tasimelteon had no signiﬁcant interaction with any other
commonly screened receptors or enzyme binding sites tested,
including a wide array of receptors of neurotransmitter systems
such as dopamine, norepinephrine, serotonin, GABA, acetylcholine,
opioid, N-methyl-D-aspartate (NMDA), hypocretin (orexin), and
cannabinoid; this ﬁnding supports the observation that tasi-
melteon did not produce signs or symptoms indicative of abuse
potential in animal or clinical studies and did not produce with-
drawal symptoms after discontinuation of chronic administration
(Hetlioz® prescribing information: https://www.hetlioz.com,
accessed Aug 27, 2014).
Tasimelteon's receptor binding proﬁle is distinct from that of
two other molecules known to bind both melatonin receptors,
ramelteon and agomelatine; ramelteon has 8 times lower afﬁnity
for the MT2 receptor than for the MT1 receptor (Kato et al, 2005),
and agomelatine, a non-speciﬁc melatonin agonist, has a 4.4 times
lower afﬁnity for the MT2 receptor than for the MT1 receptor and
binds also to several serotonin 5-HT2 receptors (Millan et al, 2003;
Bourin et al., 2004).
The selective and unique receptor binding proﬁle of tasimelteon
supports its pharmacological properties as a circadian regulator
including in particular its ability to phase advance and entrain
circadian rhythms as demonstrated in healthy volunteers
(Rajaratnam et al, 2009) and in patients with Non-24 (Lockley et al,
2013a), which leads to improvement in sleep-wake measures and
global function in patients affected with Non-24 (Lockley et al,
2013a, 2013b; Torres et al., 2014) .
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